信邦制药卷入单位行贿案，这家医药企业有太多“故事”

Core Viewpoint - Guizhou Xibang Pharmaceutical Co., Ltd. is facing potential prosecution for alleged corporate bribery, which may adversely affect its brand reputation, business expansion, and future development [1] Group 1: Company Background - Founded in 1995, Guizhou Xibang Pharmaceutical was established by Zhang Guanfeng, who acquired a failing state-owned pharmaceutical factory [2] - The company went public in April 2010, becoming the first listed company in Qiannan Prefecture [2] - In 2013, Xibang Pharmaceutical acquired 98.25% of Keke Pharmaceutical, which was formed from the sales department of the affiliated hospital of Guizhou Medical University [2] Group 2: Ownership Changes - In 2017, Zhang Guanfeng sold 21.04% of his shares to Zhu Jiman, who was the actual controller of Yuheng Pharmaceutical [3] - Zhu Jiman's control was short-lived due to liquidity issues, leading to the judicial freezing of shares in 2018 [3] - By June 2021, An Huailue and An Ji, father and daughter, became the third actual controllers of Xibang Pharmaceutical, holding a combined 25.0468% of shares [3] Group 3: Business Operations - Xibang Pharmaceutical's business spans hospitals, pharmaceutical commerce, and manufacturing [3] - As of the first half of 2025, the company reported revenue of 284.5 million yuan, a decrease of 6.62% year-on-year, and a net profit of 10.7 million yuan, down 6.69% from the previous year [3] - The company operates six medical institutions and has a comprehensive sales network covering major hospitals in Guizhou [4] Group 4: Industry Context - The pharmaceutical industry in China is undergoing a crackdown on corruption, with several high-ranking officials in Guizhou facing legal issues [5][6] - The ongoing anti-corruption efforts may impact the operational environment for companies like Xibang Pharmaceutical [5]